Literature DB >> 4547542

Immunity to murine sarcoma virus induced tumours. 3. Analysis of the cell populations involved in protection from lethal tumour progression of sublethally irradiated, MSV inoculated, mice.

R M Gorczynski, C Norbury.   

Abstract

A comparison was made between the cells responsible for demonstrable activity against MSV antigens, using both in vivo and in vitro assays. Similar cells (in terms of size and sensitivity to anti-theta serum) were detected in both assays. However, while lymphoid cells from animals at all stages post-MSV infection were active in protecting irradiated mice from the lethal effect of induction of MSV sarcomata, cells from animals at early stages post-MSV infection (when the tumour was in a progressive phase of growth) were not active in the in vitro assay. By manipulation of the in vivo assay conditions a situation was observed in which cells from "progressor animals" were able to suppress both the in vitro and in vivo activity of regressor lymphoid cells. The potential physiological role of this cell type is disussed.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4547542      PMCID: PMC2009265          DOI: 10.1038/bjc.1974.122

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Sedimentation analysis of the cells in mice required to initiate an in vivo immune response to sheep erythrocytes.

Authors:  R G Miller; R A Phillips
Journal:  Proc Soc Exp Biol Med       Date:  1970-10

2.  Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice.

Authors:  A Fefer; J L McCoy; K Perk; J P Glynn
Journal:  Cancer Res       Date:  1968-08       Impact factor: 12.701

3.  Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.

Authors:  A Fefer
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

4.  Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas.

Authors:  I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1969-09-15       Impact factor: 7.396

5.  An extension of the 51Cr-release assay for the estimation of mouse cytotoxins.

Authors:  W Boyle
Journal:  Transplantation       Date:  1968-09       Impact factor: 4.939

6.  Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas.

Authors:  I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1970-03-15       Impact factor: 7.396

7.  Separation of cells by velocity sedimentation.

Authors:  R G Miller; R A Phillips
Journal:  J Cell Physiol       Date:  1969-06       Impact factor: 6.384

8.  Macrophage migration inhibition with mouse tumor antigens: properties of serum and peritoneal cells during tumor growth and after tumor loss.

Authors:  W J Halliday
Journal:  Cell Immunol       Date:  1972-01       Impact factor: 4.868

9.  Induction of immunity and tolerance in vitro by hapten protein conjugates. I. The relationship between the degree of hapten conjugation and the immunogenicity of dinitrophenylated polymerized flagellin.

Authors:  M Feldmann
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

10.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

View more
  2 in total

1.  Immunity to murine sarcoma virus induced tumours. IV. Direct cellular cytolysis of 51Cr labelled target cells in vitro and analysis of blocking factors which modulate cytotoxicity.

Authors:  R M Gorczynski; R A Knight
Journal:  Br J Cancer       Date:  1975-04       Impact factor: 7.640

2.  Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes.

Authors:  E Fernandez-Cruz; B A Woda; J D Feldman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.